ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: Improved outcome with contemporary therapy

Leukemia

Volumn 26, Issue 2, 2012, Pages 265-270

  Bhojwani, D ^a,b   Pei, D ^a   Sandlund, J T ^a,b   Jeha, S ^a,b   Ribeiro, R C ^a,b   Rubnitz, J E ^a,b   Raimondi, S C ^a   Shurtleff, S ^a   Onciu, M ^a   Cheng, C ^a   Coustan Smith, E ^a   Bowman, W P ^c   Howard, S C ^a,b   Metzger, M L ^a,b   Inaba, H ^a,b   Leung, W ^a,b   Evans, W E ^a,b   Campana, D ^a,b   Relling, M V ^a,b   Pui, C H ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c St Jude Children's Research Hospital ^*  (United States)

Author keywords

childhood acute lymphoblastic leukemia; ETV6 RUNX1; TEL AML1

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; DEXAMETHASONE; ETOPOSIDE; METHOTREXATE; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHILD; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; DRUG SENSITIVITY; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

CHILD; CHILD, PRESCHOOL; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; TREATMENT OUTCOME;

EID: 84856756817     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.227     Document Type: Article

References (30)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 1999; 354: 1499-1503. (Pubitemid 29502102)
3. Morrow M, Horton S, Kioussis D, Brady HJ, Williams O. TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood 2004; 103: 3890-3896. (Pubitemid 38596310)
4. Ford AM, Palmi C, Bueno C, Hong D, Cardus P, Knight D et al. The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 2009; 119: 826-836.
5. Raynaud S, Cave H, Baens M, Bastard C, Cacheux V, Grosgeorge J et al. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996; 87: 2891-2899. (Pubitemid 26102240)
6. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764. (Pubitemid 46582031)
7. Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, Jonsson OG et al. Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. Blood 2004; 104: 2452-2457. (Pubitemid 39331847)
8. Ramakers-van Woerden NL, Pieters R, Loonen AH, Hubeek I, van Drunen E, Beverloo HB et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000; 96: 1094-1099. (Pubitemid 30616878)
9. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995; 92: 4917-4921.
10. Rubnitz JE, Wichlan D, Devidas M, Shuster J, Linda SB, Kurtzberg J et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol 2008; 26: 2186-2191.
11. Rubnitz JE, Downing JR, Pui CH, Shurtleff SA, Raimondi SC, Evans WE et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 1997; 15: 1150-1157. (Pubitemid 27106302)
12. Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997; 90: 571-577. (Pubitemid 27299096)
13. Forestier E, Heyman M, Andersen MK, Autio K, Blennow E, Borgstrom G et al. Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. Br J Haematol 2008; 140: 665-672. (Pubitemid 351300921)
14. Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 2006; 107: 4508-4513. (Pubitemid 43801379)
15. Pui CH, Mahmoud HH, Rivera GK, Hancock ML, Sandlund JT, Behm FG et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998; 92: 411-415. (Pubitemid 28323702)
16. Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104: 2690-2696. (Pubitemid 39434949)
17. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
18. Mathew S, Shurtleff SA, Raimondi SC. Novel cryptic, complex rearrangements involving ETV6-CBFA2 (TEL-AML1) genes identified by fluorescence in situ hybridization in pediatric patients with acute lymphoblastic leukemia. Genes Chromosomes Cancer 2001; 32: 188-193.
19. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100: 52-58. (Pubitemid 35177428)
20. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003; 101: 3809-3817. (Pubitemid 36857851)
21. Pui CH, RellingMV, Behm FG, Hancock ML, Boyett JM, Raimondi SC et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995; 9: 1680-1684.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
23. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214.
24. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11: 429-438.
25. Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011; 118: 243-251.
26. Krishna Narla R, Navara C, Sarquis M, Uckun FM. Chemosensitivity of TEL-AML1 fusion transcript positive acute lymphoblastic leukemia cells. Leuk Lymphoma 2001; 41: 615-623. (Pubitemid 32717314)
27. Fung KL, Liang RH, Chan GC. Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells. Leuk Lymphoma 2010; 51: 515-522.
28. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007; 117: 1049-1057. (Pubitemid 46556761)
29. Yang L, Panetta JC, Cai X, Yang W, Pei D, Cheng C et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008; 26: 1932-1939.
30. Whitehead VM, Payment C, Cooley L, Lauer SJ, Mahoney DH, Shuster JJ et al. The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia 2001; 15: 1081-1088. (Pubitemid 32717278)